The diagnostic role of complete MICM-P in metastatic carcinoma of bone marrow (MCBM) presented with atypical symptoms: A 7-year retrospective study of 45 cases in a single center
Open Access
- 11 November 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (45) , e31731
Abstract
Metastatic carcinoma of bone marrow (MCBM) tends to present with atypical symptoms and can be easily misdiagnosed or miss diagnosed. This study was conducted to investigate the clinical-pathological and hematological characteristics of MCBM patients in order to develop strategies for early detection, staging, treatment selection and prognosis predicting. We retrospectively analyzed 45 patients with MCBM diagnosed by bone marrow biopsy in our hospital during the past 7 years. The clinical symptoms, hemogram and myelogram features, Hematoxylin and eosin staining and immunohistochemistry staining of bone marrow biopsies, location of primary carcinoma and corresponding treatment of the 45 MCBM patients were analyzed in this study. In total, 35 (77.9%) of all patients presented pains including bone pain (73.3%) as the main manifestation, and 37 (82.2%) patients had anemia. Metastatic cancer cells were found in only 22 patients (48.9%) upon bone marrow smear examination, but in all 45 patients by bone marrow biopsy. The bone marrow of 18 (40.0%) patients was dry extraction. Distribution of metastatic carcinoma was diffuse in 20 (44.4%) patients and multi-focal in 25 (55.6%) patients, complicated with myelofibrosis in 34 (75.6%) patients. For bone marrow biopsy immunohistochemistry, 97.8% of the patients were CD45-negative, while 75.6% of the patients were Cytokeratin-positive. There were 30 patients (66.7%) identified with primary malignancies. The overall survival (OS) of 1 year for MCBM patients was 6.7%. There was a trend that patients with cancer of known primary obtained better prognosis according to the survival curve, but the finding was not statistically significant with Log-rank P = .160. Complete MICM-P plays a significant role in early diagnosis of MCBM. Bone marrow biopsy combined with immunohistochemistry is an underappreciated method for the diagnosis of MCBM, which should be taken as part of regular tests as well as bone marrow smear. Understanding the clinical-pathological and hematological characteristics of MCBM and conducting bone marrow biopsy in time are of great significance for early detection and treatment selection.Keywords
This publication has 39 references indexed in Scilit:
- Utility of bone marrow aspiration and biopsy in initial staging of Ewing sarcomaPediatric Blood & Cancer, 2014
- Interobserver Concordance in Implementing the 2010 ASCO/CAP Recommendations for Reporting ER in Breast CarcinomasAmerican Journal of Clinical Pathology, 2013
- Molecular Diagnosis of the Tissue of Origin in Cancer of Unknown Primary Site: Useful in Patient ManagementCurrent Treatment Options in Oncology, 2013
- Coagulation and cancer: biological and clinical aspectsJournal of Thrombosis and Haemostasis, 2012
- Metastasis of Solid Tumors in Bone Marrow: A Study from Northern IndiaIndian Journal of Hematology and Blood Transfusion, 2011
- Disseminated Carcinoma Diagnosed by Bone Marrow Biopsy in Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia: A Report of Two Cases with Gastric Cancer and a Review of the LiteratureJournal of Gastrointestinal Cancer, 2010
- GCDFP-15 Positive and TTF-1 Negative Primary Lung NeoplasmsApplied Immunohistochemistry & Molecular Morphology, 2009
- Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromesLeukemia Research, 2007
- Dry tap bone marrow aspiration: Clinical significanceAmerican Journal of Hematology, 1990
- Prognostic value of bone marrow biopsy in breast cancerCancer, 1982